Ankylosing Spondylitis
Immunology 8 original drugsImmunology indication. Ankylosing Spondylitis has 8 FDA-approved novel treatments, led by Johnson & Johnson, with 22 active industry clinical trials across 14 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Ankylosing Spondylitis Market Leaders
Companies with the most FDA-approved novel Ankylosing Spondylitis drugs.
Phase 3 Readouts Pro
5 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Ankylosing Spondylitis Treatments by Mechanism
Top 6 mechanisms across 18 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Ankylosing Spondylitis Clinical Pipeline by Phase
71 industry-sponsored trials across 40 sponsors
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Ankylosing Spondylitis
Novel Ankylosing Spondylitis Drugs by Company (New molecular entities)
5 companies have an FDA-approved novel drug for Ankylosing Spondylitis.
Reformulations (10 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Ankylosing Spondylitis Drug Targets
Molecular targets of approved and investigational Ankylosing Spondylitis drugs — 14 targets tracked.
Biosimilars (13 BLA approved) Click to expand
Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.
Generic Drugs (6 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs